{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:49:22Z","timestamp":1786996162640,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.radonc.2011.10.013","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T19:08:52Z","timestamp":1321556932000},"page":"444-449","source":"Crossref","is-referenced-by-count":27,"title":["Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo"],"prefix":"10.1016","volume":"102","author":[{"given":"Kristin","family":"Gurtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Hessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Eicheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"D\u00f6rfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Heider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mechthild","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2011.10.013_b0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00262-003-0494-4","article-title":"CD44v6: a target for antibody-based cancer therapy","volume":"53","author":"Heider","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2011.10.013_b0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(91)90403-L","article-title":"A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells","volume":"65","author":"G\u00fcnthert","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2011.10.013_b0015","doi-asserted-by":"crossref","first-page":"12235","DOI":"10.1016\/S0021-9258(18)31376-0","article-title":"The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat","volume":"268","author":"Screaton","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.radonc.2011.10.013_b0020","doi-asserted-by":"crossref","first-page":"12160","DOI":"10.1073\/pnas.89.24.12160","article-title":"Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons","volume":"89","author":"Screaton","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.radonc.2011.10.013_b0025","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.1241159","article-title":"Antimitotic activity of the potent tumor inhibitor maytansine","volume":"189","author":"Remillard","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.radonc.2011.10.013_b0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0305-7372(78)80014-0","article-title":"Maytansine","volume":"5","author":"Issell","year":"1978","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2011.10.013_b0035","first-page":"127","article-title":"Immunoconjugates containing novel maytansinoids: promising anticancer drugs","volume":"52","author":"Chari","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0040","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0045","first-page":"927","article-title":"Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck","volume":"30","author":"Sauter","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e32801403f4","article-title":"Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study","volume":"18","author":"Rupp","year":"2007","journal-title":"CLINICAL REPORTS. Anti-Cancer Drugs"},{"key":"10.1016\/j.radonc.2011.10.013_b0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0167-8140(94)90100-7","article-title":"Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice","volume":"32","author":"Baumann","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0360-3016(01)01686-8","article-title":"Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation","volume":"51","author":"Petersen","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.10.013_b0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2005.06.032","article-title":"Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation","volume":"76","author":"Krause","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2006.08.010","article-title":"Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice. The need for a multivariate approach in biomarker studies","volume":"81","author":"Yaromina","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2004.10.009","article-title":"Recovery from sublethal damage during fractionated irradiation of human FaDu SCC","volume":"74","author":"Petersen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2004.05.003","article-title":"Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma","volume":"72","author":"Krause","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.radonc.2007.04.014","article-title":"EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?","volume":"83","author":"Krause","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2307\/3577740","article-title":"Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units","volume":"123","author":"Baumann","year":"1990","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2007.04.020","article-title":"Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation","volume":"83","author":"Yaromina","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0100","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0360-3016(92)90653-Y","article-title":"Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation","volume":"23","author":"Baumann","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.10.013_b0105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/095530003400017812","article-title":"Differentiation status of human squamous cell carcinoma xenografts does not appear to correlate with the repopulation capacity of clonogenic tumour cells during fractionated irradiation","volume":"80","author":"Hessel","year":"2004","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2011.10.013_b0110","first-page":"6510","article-title":"Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr\/Sed nude mice","volume":"48","author":"Zietman","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2004.10.011","article-title":"Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC","volume":"74","author":"Krause","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.radonc.2010.04.020","article-title":"Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation","volume":"96","author":"Yaromina","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0125","first-page":"3961","article-title":"Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma","volume":"9","author":"Borjesson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00262-003-0396-5","article-title":"Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck","volume":"52","author":"Colnot","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2011.10.013_b0135","first-page":"1690","article-title":"Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer","volume":"44","author":"Postema","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2011.10.013_b0140","doi-asserted-by":"crossref","unstructured":"Hoinkis C, Lehmann D, Geyer P. Dose distribution within a tumor located on a mouse leg: Measurement, Monte Carlo Calculation and Literature. Radioth Oncol 2001;61, Supplement 1:95.","DOI":"10.1016\/S0167-8140(01)80934-8"},{"key":"10.1016\/j.radonc.2011.10.013_b0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0360-3016(83)90300-0","article-title":"Assessment of local tumor control using censored tumor response data","volume":"9","author":"Walker","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2011.10.013_b0150","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-10-0799","article-title":"CD44 expression predicts local recurrence after radiotherapy in larynx cancer","volume":"16","author":"De Jong","year":"2010","journal-title":"Clin Can Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0155","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1158\/1078-0432.CCR-10-2244","article-title":"CD44: A Cancer Stem Cell\u2013Related Biomarker with Predictive Potential for Radiotherapy","volume":"16","author":"Baumann","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2011.10.013_b0160","unstructured":"Heider, K. H., Kalat, M., Patzelt, A., Baum, A., K\u00fcpc\u00fc, Z., Adolf,G.R. Single-Agent Efficacy of Bivatuzumab Mertansine, an Immunoconjugate Targeting CD44v6, in Models of Human Squamous Cell Cancer. 2005;:#A52."},{"key":"10.1016\/j.radonc.2011.10.013_b0165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/09553000902836404","article-title":"Cancer stem cells and radiotherapy","volume":"85","author":"Baumann","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2011.10.013_b0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10555-008-9141-z","article-title":"Clinical biomarkers of kinase activity: examples from EGFR inhibition trials","volume":"27","author":"Krause","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.radonc.2011.10.013_b0175","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2010.02.003","article-title":"Cancer stem cells at the crossroads of current cancer therapy failures\u2013radiation oncology perspective","volume":"20","author":"Koch","year":"2010","journal-title":"Semin cancer Biol"},{"key":"10.1016\/j.radonc.2011.10.013_b0180","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3109\/09553000903232835","article-title":"Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors","volume":"85","author":"Krause","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2011.10.013_b0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.radonc.2011.05.035","article-title":"Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression","volume":"99","author":"Gurtner","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2006.07.017","article-title":"Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy","volume":"80","author":"Krause","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/02841869309093594","article-title":"Quantitative clinical radiobiology","volume":"32","author":"Bentzen","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0200","first-page":"321","article-title":"CD44 as a stem cell marker in head and neck squamous cell carcinoma","volume":"26","author":"Faber","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.radonc.2011.10.013_b0205","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1200\/JCO.2005.06.411","article-title":"Epidermal growth factor receptor expression in pretreatment biopsies from head, neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial","volume":"23","author":"Bentzen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.radonc.2009.11.007","article-title":"Glycolytic metabolism and tumour response to fractionated irradiation","volume":"94","author":"Sattler","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.radonc.2009.08.023","article-title":"Molecular radiation biology: Perspectives for radiation oncology","volume":"92","author":"Rodemann","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.radonc.2011.03.004","article-title":"Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-A systematic review and meta-analysis","volume":"100","author":"Overgaard","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0225","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.radonc.2011.05.023","article-title":"Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: Evaluation using pattern recognition in microcirculatory supply units","volume":"101","author":"Maftei","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2011.10.013_b0230","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archotol.133.12.1277","article-title":"Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer","volume":"133","author":"Lopez-Albaitero","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814011006256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814011006256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T20:47:06Z","timestamp":1639687626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814011006256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0167814011006256"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2011.10.013","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}